Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
Holding TSHA?
Track your performance easily
TSHA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.27 - $4.32
Previous Close$2.15
Volume5.46M
Average Volume (3M)2.07M
Market Cap
$440.63M
Enterprise Value$323.90M
Total Cash (Recent Filing)$172.70M
Total Debt (Recent Filing)$55.97M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Nov 13, 2024EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding204,943,306
10 Day Avg. Volume1,853,660
30 Day Avg. Volume2,070,880
Standard Deviation0.61
R-Squared0.00094
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.06
Price to Sales (P/S)34.23
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue25.16
Enterprise Value/Gross Profit20.96
Enterprise Value/Ebitda-2.99
Forecast
1Y Price Target
$6.50Price Target Upside202.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Taysha Gene Therapies News
PremiumCompany Announcements
Taysha Gene Therapies Advances in Rett Syndrome Trials
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressEnrollment remains on track, could accelerate if protocol is aligned with clinical trial experience.
Financial StabilityRecent financing extends $173M cash runway out to 4Q26.
Regulatory AdvancementsRMAT designation allows early and frequent communications with FDA senior managers, intensive guidance on efficient drug development, and eligibility for an Accelerated Approval pathway and Priority Review.
Bears Say
Clinical DataInterpatient variability makes broader interpretation of results difficult.
Clinical MeasuresSeveral flaws with Rett scales commonly used in clinical studies (e.g., RSBQ and R-MBA) were pointed out and are not regularly used in practice.
EarningsThe 2Q24 report was largely uneventful.
---
Ownership Overview
20.12% Insiders
11.08% Mutual Funds
54.79% Other Institutional Investors
14.00% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TSHA FAQ
What was Taysha Gene Therapies’s price range in the past 12 months?
Taysha Gene Therapies lowest stock price was $1.27 and its highest was $4.32 in the past 12 months.
What is Taysha Gene Therapies’s market cap?
Currently, no data Available
When is Taysha Gene Therapies’s upcoming earnings report date?
Taysha Gene Therapies’s upcoming earnings report date is Nov 13, 2024 which is 13 days ago.
How were Taysha Gene Therapies’s earnings last quarter?
Taysha Gene Therapies released its earnings results on Aug 12, 2024. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.157 by $0.067.
Is Taysha Gene Therapies overvalued?
According to Wall Street analysts Taysha Gene Therapies’s price is currently Undervalued.
Does Taysha Gene Therapies pay dividends?
Taysha Gene Therapies does not currently pay dividends.
What is Taysha Gene Therapies’s EPS estimate?
Taysha Gene Therapies’s EPS estimate is -$0.09.
How many shares outstanding does Taysha Gene Therapies have?
Taysha Gene Therapies has 204,943,310 shares outstanding.
What happened to Taysha Gene Therapies’s price movement after its last earnings report?
Taysha Gene Therapies reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.157. Following the earnings report the stock price went down -2.392%.
Which hedge fund is a major shareholder of Taysha Gene Therapies?
Among the largest hedge funds holding Taysha Gene Therapies’s share is RA Capital Management. It holds Taysha Gene Therapies’s shares valued at 24M.
---
Taysha Gene Therapies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (202.33% Upside)
$6.50 (202.33% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 903.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.73%
12-Months-Change
Fundamentals
Return on Equity
-318.69%
Trailing 12-Months
Asset Growth
145.75%
Trailing 12-Months
Company Description
Taysha Gene Therapies
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
---
TSHA Earnings Call
Q2 2024
0:00 / 0:00
---
TSHA Stock 12 Month Forecast
Average Price Target
$6.50
▲(202.33% Upside)
Technical Analysis
Best Analysts Covering TSHA
1 Year
1 Year Success Rate
5/13 ratings generated profit
1 Year Average Return
-17.65%
reiterated a buy rating 4 months ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -17.65% per trade.
---